SCHEMBL3233606

SCHEMBL3233606

CCNC(=O)c1ccc(Cl)c(C2(C)C(=O)N(S(=O)(=O)c3ccc(C(=O)NC(C)(C)C)cc3OC)c3ccc(OCC)cc32)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 2/20 0.55
GNRHR P30968 1/20 0.37
AVPR1B P47901 7/20 0.36
RAB9A P51151 1/20 0.36
PTGDR Q13258 5/20 0.35
PTGDR2 Q9Y5Y4 5/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
OXTR P30559 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233637 0.94 AVPR1A (0.55) AVPR1AGNRHRAVPR1BPTGDRPTGDR2
SCHEMBL3231628 0.93 AVPR1A (0.53) AVPR1AGNRHRAVPR1BRAB9AKDM4E
SCHEMBL3234052 0.93 AVPR1A (0.55) AVPR1AGNRHRAVPR1BPTGDR2KDM4E
SCHEMBL3230051 0.91 AVPR1A (0.55) AVPR1AAVPR1BRAB9AKDM4EMEN1
SCHEMBL3232071 0.91 AVPR1A (0.51) AVPR1AGNRHRAVPR1BRAB9AMAPT
SCHEMBL3235348 0.91 AVPR1A (0.51) AVPR1AGNRHRAVPR1BRAB9AMEN1
SCHEMBL3237260 0.91 AVPR1A (0.56) AVPR1AGNRHRAVPR1BPTGDR2KDM4E
SCHEMBL3227252 0.90 AVPR1A (0.57) AVPR1AAVPR1BRAB9AKDM4EKMT2A
SCHEMBL3235137 0.90 AVPR1A (0.57) AVPR1ARAB9AKDM4EMEN1MAPT
SCHEMBL3222842 0.89 AVPR1A (0.55) AVPR1AAVPR1BKDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097374-B1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS SANOFI AVENTIS (FR) 2010-06-09 EP claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AVPR2, AVPR1A, AVPR1B AVPR1A 2/4885GNRHR 112/4885AVPR1B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.